or Try an Advanced Search...

    Technical Analysis for LYRA - Lyra Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 0.36 -4.35% -0.02
    LYRA closed down 4.35 percent on Wednesday, May 15, 2024, on 70 percent of normal volume. The bears made the stock sink to a new 52-week low. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical LYRA trend table...
    Date Alert Name Type % Chg
    New 52 Week Closing Low Bearish 0.00%
    Narrow Range Bar Range Contraction 0.00%
    New 52 Week Low Weakness 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Bullish Engulfing Bullish -4.35%
    Calm After Storm Range Contraction -4.35%
    Narrow Range Bar Range Contraction -4.35%
    New 52 Week Low Weakness -4.35%
    Outside Day Range Expansion -4.35%
    Older End-of-Day Signals for LYRA ...

       Recent Intraday Alerts

    Alert Time
    Down 5% about 17 hours ago
    Down 3% about 17 hours ago
    Fell Below Previous Day's Low about 17 hours ago
    Down 2 % about 17 hours ago
    Down 1% about 17 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    LYRA Chart by TradingView
    Basic chart:

    Profile

    Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions using XTreo technology platform for the localized treatment of patients with ear, nose, and throat diseases. Its XTreo platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210 and LYR-220, which are bioresorbable polymeric matrices for the treatment of chronic rhinosinusitis. Lyra Therapeutics, Inc. was founded in 2005 and is headquartered in Watertown, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Sinus Headache Chronic Rhinosinusitis Sinusitis

    Is LYRA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 7 Jefferies cuts Lyra to hold in wake of failed Phase 3 study
    May 7 Target upgraded, CVS downgraded: Wall Street's top analyst calls
    May 6 Lyra Therapeutics drops 92% as phase 3 rhinosinusitis asset fails
    May 6 Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis
    Apr 30 Lyra Therapeutics GAAP EPS of -$0.35 misses by $0.08, revenue of $0.53M beats by $0.18M
    Apr 30 Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Tops Revenue Estimates
    Apr 30 Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
    Apr 26 Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    Mar 28 Lyra Therapeutics (LYRA) Soars 6.5%: Is Further Upside Left in the Stock?
    Mar 26 Private equity firms who hold 39% of Lyra Therapeutics, Inc. (NASDAQ:LYRA) gained 6.8%, institutions profited as well
    See more LYRA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 6.79
    52 Week Low 0.3467
    Average Volume 3,401,846
    200-Day Moving Average 4.23
    50-Day Moving Average 4.69
    20-Day Moving Average 3.16
    10-Day Moving Average 1.18
    Average True Range 0.41
    RSI (14) 12.28
    ADX 37.07
    +DI 10.71
    -DI 55.67
    Chandelier Exit (Long, 3 ATRs) 4.54
    Chandelier Exit (Short, 3 ATRs) 1.58
    Upper Bollinger Bands 7.70
    Lower Bollinger Band -1.39
    Percent B (%b) 0.19
    BandWidth 287.82
    MACD Line -1.39
    MACD Signal Line -1.06
    MACD Histogram -0.3296
    Fundamentals Value
    Market Cap 18.7 Million
    Num Shares 52.6 Million
    EPS -1.40
    Price-to-Earnings (P/E) Ratio -0.25
    Price-to-Sales 178.41
    Price-to-Book 3.04
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.40
    Resistance 3 (R3) 0.40 0.39 0.39
    Resistance 2 (R2) 0.39 0.38 0.39 0.39
    Resistance 1 (R1) 0.37 0.37 0.37 0.37 0.39
    Pivot Point 0.36 0.36 0.36 0.36 0.36
    Support 1 (S1) 0.34 0.35 0.34 0.34 0.33
    Support 2 (S2) 0.33 0.34 0.33 0.32
    Support 3 (S3) 0.32 0.33 0.32
    Support 4 (S4) 0.31